Compare BridgeBio Pharma Inc (BBIO) vs Booking Holdings Inc (BKNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Booking Holdings Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Booking Holdings Inc trades at $211.66 (market cap $159.95B). The key difference: Booking Holdings Inc is far larger — about 9.6× BridgeBio Pharma Inc's market cap, and Booking Holdings Inc pays a 0.79% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | BKNG | |
|---|---|---|
Market Cap | $16.61B | $159.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $228.83 |
52-Week Low | $47.29 | $154.13 |
Enterprise Value | $18.16B | $163.43B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
BKNG trades at $214.42, up 3.39% on strong Q2 2026 earnings beats, with bullish technical signals and a consensus price target of $239.31. Revenue growth accelerated to $26.92B in 2025, though net income dipped to $5.40B. The stock shows robust profitability with a 25.53% net margin and high ROE, but faces geopolitical and competitive pressures.
Outlook remains positive with resilient travel demand and AI integration driving efficiency, but risks include Middle East volatility and high debt levels. Analysts are overwhelmingly bullish with 64% buy ratings, supporting upside potential amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →
